WallStSmart

Harrow Health Inc (HROW)vsViatris Inc (VTRS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 5247% more annual revenue ($14.74B vs $275.59M). VTRS leads profitability with a -2.8% profit margin vs -13.5%. VTRS earns a higher WallStSmart Score of 48/100 (D+).

HROW

Avoid

23

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: 0.76

VTRS

Hold

48

out of 100

Grade: D+

Growth: 2.7Profit: 3.5Value: 4.3Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HROW.

VTRSSignificantly Overvalued (-84.5%)

Margin of Safety

-84.5%

Fair Value

$8.74

Current Price

$17.83

$9.09 premium

UndervaluedFair: $8.74Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HROW0 strengths · Avg: 0/10

No standout strengths identified

VTRS1 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Areas to Watch

HROW4 concerns · Avg: 2.3/10
Market CapQuality
$1.41B3/10

Smaller company, higher risk/reward

Price/BookValuation
80.7x2/10

Trading at 80.7x book value

Return on EquityProfitability
-35.4%2/10

ROE of -35.4% — below average capital efficiency

EPS GrowthGrowth
-10.3%2/10

Earnings declined 10.3%

VTRS4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : HROW

Revenue growth of 10.9% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bear Case : HROW

The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 19.79 is elevated, increasing financial risk.

Bear Case : VTRS

The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.

Key Dynamics to Monitor

VTRS carries more volatility with a beta of 0.88 — expect wider price swings.

HROW is growing revenue faster at 10.9% — sustainability is the question.

VTRS generates stronger free cash flow (329M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (48/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Harrow Health Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?